Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment ft.trib.al/NrryoqW
Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment
Soleno Therapeutics makes first commercialised drug for extreme hunger caused by Prader-Willi syndrome
ft.trib.al
April 6, 2026 at 3:00 AM
Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment ft.trib.al/NrryoqW
Neurocrine Biosciences Showcases PWS Research and VYKAT XR at 2026 Conference#USA#Philadelphia#Neurocrine#VYKAT_XR#Prader-Willi_Syndrome
Neurocrine Biosciences Showcases PWS Research and VYKAT XR at 2026 Conference
Neurocrine Biosciences presents crucial research at the Foundation for Prader-Willi Research Symposium focusing on VYKAT XR for Prader-Willi Syndrome.
third-news.com
September 30, 2026 at 12:44 PM
Neurocrine Biosciences Showcases PWS Research and VYKAT XR at 2026 Conference#USA#Philadelphia#Neurocrine#VYKAT_XR#Prader-Willi_Syndrome
Neurocrine to buy Soleno Therapeutics for $2.9 billion reut.rs/4ctaQKc
Neurocrine to buy Soleno Therapeutics for $2.9 billion
Neurocrine Biosciences will acquire rare disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday, marking the neuroscience-focused drugmaker's expansion into metabolic disorders.
reut.rs
April 6, 2026 at 11:15 AM
Neurocrine to buy Soleno Therapeutics for $2.9 billion reut.rs/4ctaQKc
Ruder Finn Wins Neurocrine Biosciences US AOR
Ruder Finn Wins Neurocrine Biosciences US AOR
The agency will handle product and pipeline communications, corporate reputation, digital and creative work.
www.provokemedia.com
September 29, 2026 at 2:16 PM
Ruder Finn Wins Neurocrine Biosciences US AOR
❗️Job Alert❗ Neurocrine Biosciences has 7 new jobs open!
Dive into the details below👇
#AcademicSky #ScienceJobs
1/8
Dive into the details below👇
#AcademicSky #ScienceJobs
1/8
February 15, 2025 at 4:30 PM
❗️Job Alert❗ Neurocrine Biosciences has 7 new jobs open!
Dive into the details below👇
#AcademicSky #ScienceJobs
1/8
Dive into the details below👇
#AcademicSky #ScienceJobs
1/8
OZEMPIC is owned by Novo Nordisk.
INGREZZA is owned by Neurocrine Biosciences.
ADVIL is owned by Pfizer.
INGREZZA is owned by Neurocrine Biosciences.
ADVIL is owned by Pfizer.
February 23, 2025 at 9:53 PM
OZEMPIC is owned by Novo Nordisk.
INGREZZA is owned by Neurocrine Biosciences.
ADVIL is owned by Pfizer.
INGREZZA is owned by Neurocrine Biosciences.
ADVIL is owned by Pfizer.
Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover reut.rs/4sY2qk9
Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover
Soleno Therapeutics said on Tuesday it has voluntarily withdrawn the European marketing application for its rare metabolic disorder drug following acquirer Neurocrine's plans to sharpen focus on the U.S. market.
reut.rs
April 7, 2026 at 10:25 PM
Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover reut.rs/4sY2qk9
neurocrine.gcs-web.com/news-release...
Topline results from our partners at Neurocrine - first of our extensive muscarinic portfolio assets developed by Nxera and our NxWave platform bring on phase 3!
Topline results from our partners at Neurocrine - first of our extensive muscarinic portfolio assets developed by Nxera and our NxWave platform bring on phase 3!
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia | Neurocrine Biosciences
The Investor Relations website contains information about Neurocrine Biosciences's business for stockholders, potential investors, and financial analysts.
neurocrine.gcs-web.com
August 29, 2024 at 9:56 PM
neurocrine.gcs-web.com/news-release...
Topline results from our partners at Neurocrine - first of our extensive muscarinic portfolio assets developed by Nxera and our NxWave platform bring on phase 3!
Topline results from our partners at Neurocrine - first of our extensive muscarinic portfolio assets developed by Nxera and our NxWave platform bring on phase 3!
Neurocrine Biosciences Welcomes Dr. Eiry W. Roberts Back as Chief Medical Officer#United_States#San_Diego#Neurocrine_Biosciences#INGREZZA#Eiry_W._Roberts
Neurocrine Biosciences Welcomes Dr. Eiry W. Roberts Back as Chief Medical Officer
Neurocrine Biosciences has appointed Dr. Eiry W. Roberts as Chief Medical Officer again, bringing her extensive experience back to the team. This move comes as the company prepares for important clinical milestones.
third-news.com
September 28, 2026 at 8:16 PM
Neurocrine Biosciences Welcomes Dr. Eiry W. Roberts Back as Chief Medical Officer#United_States#San_Diego#Neurocrine_Biosciences#INGREZZA#Eiry_W._Roberts
In this week's Peer Review: Juan Andres returns to Moderna as COO, Eiry Roberts is back as Neurocrine's CMO, and Pharming CEO Fabrice Chouraqui exits.
endpoints.news/moderna-neur...
endpoints.news/moderna-neur...
Moderna, Neurocrine bring back familiar faces; Pharming CEO exits after clashing with board
Juan Andres will come out of retirement to rejoin Moderna as COO on Oct. 5, bringing his intimate knowledge of the company as its Merck-partnered cancer vaccine gathers momentum in the clinic.
endpoints.news
October 2, 2026 at 2:05 PM
In this week's Peer Review: Juan Andres returns to Moderna as COO, Eiry Roberts is back as Neurocrine's CMO, and Pharming CEO Fabrice Chouraqui exits.
endpoints.news/moderna-neur...
endpoints.news/moderna-neur...
Neurocrine Biosciences will acquire rare-disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday, marking the neuroscience-focused drugmaker's expansion into metabolic disorders.
Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout
Neurocrine Biosciences will acquire rare-disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday, marking the neuroscience-focused drugmaker's expansion into metabolic disorders.
reut.rs
April 6, 2026 at 12:10 PM
Neurocrine Biosciences will acquire rare-disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday, marking the neuroscience-focused drugmaker's expansion into metabolic disorders.
NEUROCRINE BIOSCIENCES INC (0000914475) (Filer) (cik: 0000914475) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/914475/000091447526000045/0000914475-26-000045-index.htm
September 28, 2026 at 8:41 PM
NEUROCRINE BIOSCIENCES INC (0000914475) (Filer) (cik: 0000914475) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/914475/000091447526000045/0000914475-26-000045-index.htm
Neurocrine Biosciences Welcomes Dr. Sanjay Keswani as New Chief Medical Officer#USA#San_Diego#CMO#Neurocrine#Sanjay_Keswani
Neurocrine Biosciences Welcomes Dr. Sanjay Keswani as New Chief Medical Officer
Neurocrine Biosciences appoints Dr. Sanjay Keswani as CMO, bringing over two decades of RD expertise to strengthen their leadership.
third-news.com
April 4, 2025 at 12:18 PM
Neurocrine Biosciences Welcomes Dr. Sanjay Keswani as New Chief Medical Officer#USA#San_Diego#CMO#Neurocrine#Sanjay_Keswani
Thanks to our RISW supporting sponsors: Argenx; Astellas; BlankBio; CIMS; Clindata; DuBu Research; HopeAI; Innovatio Statistics; Neurocrine Biosciences; NouStarX; Otsuka; Penfield; Phase V; Phastar; Quantive Intelligence; Regeneron; Servier; Stata; The Lotus Group; VeraMed; & Vertex.
September 18, 2026 at 10:18 PM
Thanks to our RISW supporting sponsors: Argenx; Astellas; BlankBio; CIMS; Clindata; DuBu Research; HopeAI; Innovatio Statistics; Neurocrine Biosciences; NouStarX; Otsuka; Penfield; Phase V; Phastar; Quantive Intelligence; Regeneron; Servier; Stata; The Lotus Group; VeraMed; & Vertex.
Neurocrine Biosciences Launches CRENESSITY™ for Classic CAH Treatment in the U.S.#United_States#San_Diego#Crenessity#CAH#Neurocrine
Neurocrine Biosciences Launches CRENESSITY™ for Classic CAH Treatment in the U.S.
Neurocrine Biosciences has launched CRENESSITY™, a groundbreaking treatment for classic congenital adrenal hyperplasia (CAH), now available in the U.S. for eligible patients.
third-news.com
December 20, 2024 at 1:15 PM
Neurocrine Biosciences Launches CRENESSITY™ for Classic CAH Treatment in the U.S.#United_States#San_Diego#Crenessity#CAH#Neurocrine
The groups did not tell anyone to stop. They asked for careful patient selection and closer monitoring. Neurocrine says it stands behind the safety profile, and the FDA hadn't issued a communication or label change as of mid-August. (Not medical advice.)
September 29, 2026 at 1:00 PM
The groups did not tell anyone to stop. They asked for careful patient selection and closer monitoring. Neurocrine says it stands behind the safety profile, and the FDA hadn't issued a communication or label change as of mid-August. (Not medical advice.)
Thanks to our #RISW2026 supporting sponsors: Argenx; Astellas; BlankBio; CIMS; Clindata; DuBu Research; HopeAI; Innovatio Statistics; Neurocrine Biosciences; NouStarX; Otsuka; Penfield; Phase V; Phastar; Quantive Intelligence; Regeneron; Servier; Stata; The Lotus Group; VeraMed; & Vertex. #STATSSKY
September 17, 2026 at 7:57 PM
#NBIX Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia
https://www.stocktitan.net/news/NBIX/neurocrine-biosciences-presents-real-world-data-on-therapeutic-dose-o12wnr24wo9c.html
https://www.stocktitan.net/news/NBIX/neurocrine-biosciences-presents-real-world-data-on-therapeutic-dose-o12wnr24wo9c.html
New Data: INGREZZA Outperforms Competitors with Perfect Therapeutic Dose Rate
Real-world study reveals INGREZZA's superior dosing efficiency: 100% therapeutic success from day one, with better stability vs competitors. Full analysis inside.
www.stocktitan.net
March 31, 2025 at 12:30 PM
#NBIX Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia
https://www.stocktitan.net/news/NBIX/neurocrine-biosciences-presents-real-world-data-on-therapeutic-dose-o12wnr24wo9c.html
https://www.stocktitan.net/news/NBIX/neurocrine-biosciences-presents-real-world-data-on-therapeutic-dose-o12wnr24wo9c.html
Neurocrine Biosciences Reveals Essential Data on Mild Tardive Dyskinesia Treatment with INGREZZA#USA#San_Diego#Neurocrine#INGREZZA#Tardive_Dyskinesia
Neurocrine Biosciences Reveals Essential Data on Mild Tardive Dyskinesia Treatment with INGREZZA
Recent findings from Neurocrine Biosciences show that nearly all patients with mild tardive dyskinesia experience significant improvements with INGREZZA, enhancing their daily lives.
third-news.com
May 18, 2026 at 8:12 PM
Neurocrine Biosciences Reveals Essential Data on Mild Tardive Dyskinesia Treatment with INGREZZA#USA#San_Diego#Neurocrine#INGREZZA#Tardive_Dyskinesia
I think Neurocrine is hiring someone to do rodent EEG.
January 17, 2026 at 10:53 PM
I think Neurocrine is hiring someone to do rodent EEG.
Neurocrine Biosciences Reveals Encouraging Data on CRENESSITY® for Pediatric CAH Patients at ENDO 2026#USA#Chicago#Neurocrine_Biosciences#CAHtalyst_Study#CRF1_Antagonist
Neurocrine Biosciences Reveals Encouraging Data on CRENESSITY® for Pediatric CAH Patients at ENDO 2026
New findings from Neurocrine Biosciences demonstrate that CRENESSITY® significantly improves growth measures in pediatric patients with classic congenital adrenal hyperplasia.
third-news.com
June 15, 2026 at 12:49 PM
Neurocrine Biosciences Reveals Encouraging Data on CRENESSITY® for Pediatric CAH Patients at ENDO 2026#USA#Chicago#Neurocrine_Biosciences#CAHtalyst_Study#CRF1_Antagonist
Neurocrine Biosciences Unveils Two-Year CRENESSITY Data at ENDO 2026: Promising Cardiometabolic Improvements#USA#Chicago#Crenessity#Neurocrine_Biosciences#Congenital_Adrenal_Hyperplasia
Neurocrine Biosciences Unveils Two-Year CRENESSITY Data at ENDO 2026: Promising Cardiometabolic Improvements
Neurocrine Biosciences presented new data showcasing significant cardiometabolic improvements over two years with CRENESSITY in adults with CAH at ENDO 2026.
third-news.com
June 15, 2026 at 12:37 PM
Neurocrine Biosciences Unveils Two-Year CRENESSITY Data at ENDO 2026: Promising Cardiometabolic Improvements#USA#Chicago#Crenessity#Neurocrine_Biosciences#Congenital_Adrenal_Hyperplasia
Neurocrine has offered $53 per Soleno share held, which represents a premium of about 34% to the stock's last close.
Neurocrine to buy Soleno Therapeutics for $2.9 billion
Neurocrine has offered $53 per Soleno share held, which represents a premium of about 34% to the stock's last close.
cnb.cx
April 6, 2026 at 11:27 AM
Neurocrine has offered $53 per Soleno share held, which represents a premium of about 34% to the stock's last close.